Allogene Therapeutics ALLO Business Segments — Other operating expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherCostAndExpenseOperating.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's business segments — other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Allogene Therapeutics's business segments — other operating expenses?
- Allogene Therapeutics (ALLO) reported business segments — other operating expenses of $11.19M in Q1 2026.
- How has Allogene Therapeutics's business segments — other operating expenses changed year-over-year?
- Allogene Therapeutics's business segments — other operating expenses decreased by 29.2% year-over-year, from $15.81M to $11.19M.
- What is the long-term trend for Allogene Therapeutics's business segments — other operating expenses?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — other operating expenses has grown at a -25.0% compound annual growth rate (CAGR), from $95.37M to $53.59M.
- What does business segments — other operating expenses mean?
- This metric aggregates miscellaneous operating costs not captured in specific functional categories like payroll or R&D. It includes general administrative overhead and other incidental expenses necessary for day-to-day business continuity. Monitoring this helps identify potential inefficiencies or unexpected administrative burdens.